+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 - 2024)

  • ID: 4846206
  • Report
  • September 2019
  • Region: Global
  • 120 pages
  • Azoth Analytics
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Novartis
  • Novo Nordisk
  • Pfizer
  • Saniona
  • Soleno Therapeutics
  • MORE
Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Prader-Willi Syndrome market. The report analyses the Global Prader-Willi Syndrome Therapeutics Market in terms of its sizing, growth and forecast. The report presents a comprehensive pipeline assessment that includes DCCR (Soleno Therapeutics), Levolitide (Millendo Therapeutics) and Tesomet (Saniona). Also, the report analyzes the prevalence of PWS and profiles the leading companies operating in the PWS Therapeutics market. The report analyzes the Global Market, European Region Market and the country analysis of United States and Japan for the historical period of 2017 and 2018 and the forecast period of 2019-2024.

According to the report, the Prader-Willi Syndrome therapeutics market is projected to display a robust growth represented by a CAGR of 4.6% during 2019 - 2024.

Over the recent years, the Prader-Willi Syndrome market has been witnessing considerable growth directly on the back of the increasing number of diagnosed patient’s population. Moreover, growing human growth hormone therapy coverage rate, surging awareness and increasing government involvement have been driving the market.

Further, expected launch of novel therapies, such as DCCR (Soleno Therapeutics), Livoletide (Millendo Therapeutics), Testomet (Saniona AB) among others are anticipated to fuel the market growth.

The report titled report “Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 - 2024)” has covered and analyzed the potential of Prader-Willi Syndrome market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges, opportunities and market entry strategies for various companies. Additionally, the report also highlights the estimated prevalence of Prader-Willi Syndrome in USA, Europe and Japan.

Scope of the Report

Global Prader-Willi Syndrome Market (Actual Period: 2017-2018, Forecast Period: 2019-2024)
  • Prader-Willi Syndrome Market - Size, Growth, Forecast
  • Prader-Willi Syndrome Market: Pipeline Analysis
  • DCCR (Soleno Therapeutics)
  • Levolitide (Millendo Therapeutics)
  • Tesomet (Saniona)
Regional Prader-Willi Syndrome Market - U.S.A, Europe, Japan (Actual Period: 2017-2018, Forecast Period: 2019-2024)
  • Prader-Willi Syndrome Market - Size, Growth, Forecast
  • Prader-Willi Syndrome Market: Pipeline Analysis
  • DCCR (Soleno Therapeutics)
  • Levolitide (Millendo Therapeutics)
  • Tesomet (Saniona)
Other Report Highlights
  • Pipeline Analysis.
  • Competitive Landscape.
  • Product Benchmarking.
  • Market Dynamics - Drivers and Restraints.
  • Market Trends.
  • Porter Five Forces Analysis.
  • SWOT Analysis.
  • Company Analysis - Pfizer, Novartis, Novo Nordisk, Soleno Therapeutics, Saniona
Customization of the Report
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Novartis
  • Novo Nordisk
  • Pfizer
  • Saniona
  • Soleno Therapeutics
  • MORE
1. Research Methodology

2. Executive Summary

3. Strategic Recommendations
3.1 Invest in Somatropin Biosimilar
3.2 Invest in Combination Therapy For PWS

4. Surgical Masks Product Outlook

5. Global Prader-Willi Syndrome Market: Growth and Forecast
5.1 By Value (2017-2018)
5.2 By Value (2019-2024)

6. Global Prader-Willi Syndrome Pipeline Analysis
6.1 DCCR Pipeline Analysis
6.2 Levolitide Pipeline Analysis
6.3 Tesomet Pipeline Analysis

7. Global Prader-Willi Syndrome Market, By Region

8. U.S.A Prader-Willi Syndrome Market
8.1 U.S.A Prader-Willi Syndrome Market Size (2017-2024F)
8.2 U.S.A Prader-Willi Syndrome Prevalence (2017-2024F)

9. Europe Prader-Willi Syndrome Market
9.1 Europe Prader-Willi Syndrome Market Size (2017-2024F)
9.2 Europe Prader-Willi Syndrome Prevalence (2017-2024F)

10. Japan Prader-Willi Syndrome Market
10.1 Japan Prader-Willi Syndrome Market Size (2017-2024F)
10.2 Japan Prader-Willi Syndrome Prevalence (2017-2024F)

11. Global Prader-Willi Syndrome Market - Competitive Landscape

12. Global Prader-Willi Syndrome Market - Product Benchmarking

13. Global Prader-Willi Syndrome Market: Market Dynamics
13.1 Global Prader-Willi Syndrome Market Drivers
13.2 Global Prader-Willi Syndrome Market Restrains
13.3 Global Prader-Willi Syndrome Market Trends

14. Porter Five Force Analysis

15. SWOT Analysis

16. Global Prader-Willi Syndrome Market: Regulatory Frameworks

17. Company Profiles
17.1 Pfizer
17.2 Novartis AG
17.3 Novo Nordisk
17.4 Soleno Therapeutics
17.4 Saniona
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer
  • Novartis
  • Novo Nordisk
  • Soleno Therapeutics
  • Saniona
Note: Product cover images may vary from those shown
5 of 4

Loading
LOADING...

Adroll
adroll